Peroxisome proliferator-activated receptor-γ protects against hepatic ischemia/reperfusion injury in mice

Hepatology

Volumn 47, Issue 1, 2008, Pages 215-224

  Kuboki, Satoshi ^a   Shin, Thomas ^a   Huber, Nadine ^a   Eismann, Thorsten ^a   Galloway, Elizabeth ^a   Schuster, Rebecca ^a   Blanchard, John ^a   Zingarelli, Basilia ^a   Lentsch, Alex B ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; HETERODIMER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN P300; RETINOID X RECEPTOR ALPHA; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG TARGETING; LIVER CELL; LIVER ISCHEMIA; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPERFUSION; REPERFUSION INJURY;

ANIMALS; C-PEPTIDE; E1A-ASSOCIATED P300 PROTEIN; GENE EXPRESSION REGULATION; HEPATOCYTES; LIVER; LIVER DISEASES; MALE; MICE; MICE, INBRED C57BL; PPAR GAMMA; PROSTAGLANDIN D2; REPERFUSION INJURY; RETINOID X RECEPTOR ALPHA; THIAZOLIDINEDIONES;

EID: 38649129082     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21963     Document Type: Article

References (49)

1. Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. HEPATOLOGY 2000;32:169-173.
2. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003;284:G15-G26.
3. Wanner GA, Ertel W, Muller P, Hofer Y, Leiderer R, Menger MD, et al. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock 1996;5:34-40.
4. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-6866.
5. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-246.
6. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr. Role of tumor necrosis factor-alpha in the pathophysiologic alternations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990;85:1936-1943.
7. Colletti LM, Cortis A, Lukacs N, Kunkel SL, Green M, Strieter RM. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998;10:182-191.
8. Colletti LM, Kunkel SL, Waltz A, Burdick MD, Kunkel RG, Wilke CA, et al. Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein. J Clin Invest 1995;95:134-141.
9. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. HEPATOLOGY 1998;27:1172-1177.
10. Lentsch AB, Yoshidome H, Kato A, Warner RL, Cheadle WG, Ward PA, et al. Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. HEPATOLOGY 1999;30:1448-1453.
11. Kato A, Gabay C, Okaya T, Lentsch AB. Specific role of interleukin-1 in hepatic neutrophil recruitment after ischemia/reperfusion. Am J Pathol 2002;161:1797-1803.
12. Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L, Engelhardt JF. CD4+ T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 1997;100:279-289.
13. Caldwell CC, Okaya T, Martignoni A, Husted T, Schuster R, Lentsch AB. Divergent functions of CD4+ T lymphocytes in acute liver inflammation and injury after ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2005;289:G969-G976.
14. Jaeschke H, Smith CW. Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997;61:647-653.
15. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-895.
16. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-839.
17. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
18. von Knethen A, Brune B. PPARgamma - an important regulator of monocyte/macrophage function. Arch Immunol Ther Exp (Warsz) 2003;51:219-226.
19. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995;83:813-819.
20. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996;137:4189-4195.
21. Reynaert H, Geerts A, Henrion J. Review article: the treatment of non-alchoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther 2005;22:897-905.
22. Geng DF, Wu W, Jin DM, Wang JF, Wu YM. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int J Cardiol 2006;113:86-91.
23. Nakajima A, Wada K, Miki H, Kubota N, Nakijima N, Terauchi Y, et al. Endogeneous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001;120:460-469.
24. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattri Y, Brown PA, et al. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 2003;23:267-276.
25. Okada M, Yan SF, Pinsky DJ. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Erg-1 and its inflammatory gene targets. FASEB J 2002;16:1861-1868.
26. Wahren J, Ekberg K, Johansson J, Henriksson M, Pramanik A, Johansson BL, et al. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000;278:E759-E768.
27. Al-Rasheed NM, Chana RS, Baines RJ, Willars GB, Brunskill NJ. Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem 2004;279:49747-49754.
28. Young LH, Ikeda Y, Scalia R, Lefer AM. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2000;279:1453-1459.
29. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004;116:511-526.
30. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, Kato S. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biol Chem 2000;275:33201-33204.
31. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992;358:771-774.
32. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-gamma. Nature 1998;395:137-143.
33. Palmer CN, Hsu MH, Griffin HJ, Johnson EF. Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 1995;270:16114-16121.
34. Wu Y, Zhang X, Bardag-Gorce F, Robel RC, Aguilo J, Chen L, et al. Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver. Mol Pharmacol 2004;65:550-557.
35. Wan YJ, An D, Cai Y, Repa JJ, Hung-Po Chen T, Flores M, et al. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol Cell Biol 2000;20:4436-4444.
36. Deryckere F, Gannon F. A one-hour minipreparation technique for extraction of DNA-binding proteins from animal tissues. BioTechniques 1994;16:405.
37. Schierwagen C, Bylund-Fellenius AC, Lundberg C. Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol Methods 1990;23:179-186.
38. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem 2000;275:16390-16399.
39. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 2000;20:4699-4707.
40. Feingold K, Kim MS, Shigenaga J, Moster A, Grunfeld C. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab 2004;286:E201-E207.
41. The Jackson Laboratory. Technical document 006142. Available at: http://jaxmice.jax.org/strain/006142.html. Accessed August 2007.
42. 2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83:803-812.
43. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005;65:772-781.
44. Uchimura K, Nakamuta M, Enjoji M, Irie T, Sugimoto R, Muta T, et al. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. HEPATOLOGY 2001;33:91-99.
45. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999;4:585-595.
46. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 2005;90:6678-6686.
47. Carini R, Grazia De Cesaris M, Splendore R, Baldanzi G, Nitti MP, Alchera E, et al. Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning. Gastroenterology 2004;127:914-923.
48. Izuishi K, Tsung A, Hossain MA, Fujiwara M, Wakabayashi H, Masaki T, et al. Ischemic preconditioning of the murine liver protects through the Akt kinase pathway. HEPATOLOGY 2006;44:573-580.
49. Müller C, Dünschede F, Koch E, Vollmar AM, Kiemer AK. Alpha-lipoic acid preconditioning reduces ischemia-reperfusion injury of the rat liver via the PI3-kinase/Akt pathway. Am J Physiol Gastrointest Liver Physiol 2003;285:G769-G778.